NEXLIZET (bempedoic acid and ezetimibe) tablets, 180 mg/10 mg, 30-count bottle, Rx only, Manufact...

FDA Recall #D-0441-2024 — Class III — March 27, 2024

Recall #D-0441-2024 Date: March 27, 2024 Classification: Class III Status: Completed

Product Description

NEXLIZET (bempedoic acid and ezetimibe) tablets, 180 mg/10 mg, 30-count bottle, Rx only, Manufactured for: Esperion Therapeutics, Ann Arbor, MI 48108, NDC 72426-818-03

Reason for Recall

Failed dissolution specifications: out-of-specification bempedoic acid dissolution at the 0-month timepoint.

Recalling Firm

Esperion — Ann Arbor, MI

Classification

Class III — Not likely to cause adverse health consequences.

Product Type

Drugs

Product Quantity

3,480 30-count bottles

Distribution

Nationwide in the USA

Code Information

Lot #, 1990305, Exp 08-31-2025

Status

Completed

Voluntary / Mandated

Voluntary: Firm initiated